Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 277
Published on December 8, 2017 at 05:00 AM GMT

Ozempic (semaglutide) GLP-1 type 2 diabetes drug from Novo Nordisk can reduce obesity and body fat levels

Ozempic semaglutide diabetes drug can reduce hungriness, moreishness, food craving, obesity, body fat. An independent research funded by Novo Nordisk, by scientists at the University of Leeds shows marked weight loss among clinically obese individuals with a semaglutide type 2 diabetes (T2D) drug. This drug is similar to naturally-occurring hormone GLP-1 in the body, which targets sensory receptors of appetite control mechanism (in the hypothalamus portion of the brain) to reduce hungriness, moreishness or food cravings. Novo Nordisk makes semaglutide drug with a brand name Ozempic.

Scientists have conducted a study with a weekly dose semaglutide drug among 28 obese or overweight people with a body mass index (BMI) between 30 to 45 kg/m2 . At the end of 12 weeks study, they found an average 24 percent reduction in their daily energy intake with semaglutide drug. In those experiments, the semaglutide drug demonstrated better control over appetite. People under this treatment preferred smaller meals and their preference to foods with high fat content has been reduced. Scientists have successfully reduced 5 kgs or 11 lbs of weight, mostly body fat, over a period of 12 weeks with semaglutide drug.

Once in a week semaglutide injection costs about $676 per prescription. Oral form of the drug is under development. This drug is going to compete with other GLP-1 drugs in the market, dulaglutide from Trulicity and bydureon from AstraZeneca. FDA has approved Novo Nordisk's semaglutide drug on December 5, 2017.

Lead author of the study was Professor John Blundell, Psycho-Biology (Biological Psychology), the University of Leeds, United Kingdom. The study findings were published on May 5, 2017 in the journal Diabetes, Obesity and Metabolism. Title of the article was "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity."

If you like this article, please share it with a friend! Article address is (copy and past the code below):

Also related to this story
1. Treatment With Semaglutide Pill
2. Lose 15 kg (33 lb) in body weight (weight loss) by eating low calorie diet to reverse type 2 diabetes and extend life expectancy by six years
3. Weight loss and improved blood sugar glucose levels (glycemic control) with an EndoBarrier device
4. Study shows altering sense of smell helps weight loss and type 2 diabetes
5. Prevention Of Type 2 Diabetes With Weight Loss Drug
6. Benefits With Bariatric (Weight Loss) Surgery
7. Benefits With Weight Loss During Pregnancy
8. Eating cocoa chocolate reduces blood sugar or glucose levels, obesity and increases insulin secretion
9. Ginger Fights Body Metabolic Syndrome, Fat, Obesity and Diabetes
10. Obesity Worsen Type 2 Diabetes (T2D) Related Brain Abnormalities - Dementia, Cognitive

Clinically obese : An individual with a higher body mass index (BMI) causing medical complications.

Moreishness : Preferring particular foods having high fat content.


Radical "hot water bottle" treatment for type 2 diabetes patients could reduce insulin injections, medical costs and drug usage
Hot water bottle treatment for type 2 diabetes could reduce medical expenses insulin injections drugs. Doctors at the London hospital are conducting a radical treatment procedure to patients with type 2 diabetes (T2D) to prevent further worsening of the condition, reduce medical expenses and to reduce need for medicines and insulin injection requirements. The first procedure was conducted at the University College Hospital (UCH), Bloomsbury, London, UK.

This procedure was not intended to cure type 2 diabetes (T2D). This procedure takes less than 60 minutes for completion. This procedure involves brief insertion of a tiny hot water bottle into the upper intestine via the mouth, stomach and duodenum. The duodenum lining tissue will be removed by the hot water balloon, which is at 90°C, causing release of insulin to control blood sugar levels.

Patients with polycystic ovary syndrome (PCOS) or non-alcohol-related fatty liver disease (NAFLD) may also be benefited with this treatment. Dr Rehan Haidry, a gastroenterologist, is leading a team of doctors in conducting the trials at the University College Hospital (UCH), Bloomsbury, London, UK. Contact cormac[dot]magee[at]nhs[dot]net to participate in the trial.

Post a message on social media and mail to your friend. Article address is (copy and past the code below):

Also related to this story
1. Ghrelin Hormone Could Expand Diabetes Treatments And Hypoglycemia
2. Regulation Of Insulin And Treatment Of Type 2 Diabetes With Stevia Extract
3. Prevention And Treatment Of Type 1 Diabetes With Omega 3 Fatty Acids
4. Medical Cost Savings With Triglyceride And Statin Reducing Treatments
5. Risk To Pancreas Inflammation With Gliptin Treatment
6. About Revita DMR Device
7. Kidney failure, amputations, blindness, heart attack and stroke complications by delaying insulin therapy among type 2 diabetes patients
8. Raspberries could lower inflammation, high blood sugar or glucose levels and improves insulin sensitivity
9. High-intensity interval training (HIIT) workout reduces waist circumference, systolic blood pressure, insulin and blood sugar glucose levels
10. Study shows link between retinal vein occlusion (RVO) and acute myocardial infarction (AMI) or heart attack



Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4


Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.

Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.